Travere Therapeutics, Inc.
TVTX
$62.14
$0.711.16%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -172.81% | 10.00% | 104.53% | 146.90% | 81.88% |
| Total Depreciation and Amortization | -69.79% | 96.94% | 50.00% | 40.48% | 35.49% |
| Total Amortization of Deferred Charges | -- | -- | -4.93% | -- | -- |
| Total Other Non-Cash Items | 542.48% | 67.71% | -535.65% | 30.14% | -88.38% |
| Change in Net Operating Assets | 605.46% | -90.43% | 611.61% | -454.05% | 90.72% |
| Cash from Operations | 1,065.38% | 4.33% | 269.87% | 133.68% | 112.38% |
| Capital Expenditure | -- | -- | 357.32% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4,353.34% | -47.81% | -30.88% | 88.03% | -83.10% |
| Cash from Investing | -4,353.34% | -47.81% | -30.54% | 87.73% | -83.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,409.85% | 11.45% | -80.52% | 616.29% | 53.02% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,099.05% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash from Financing | 12,613.02% | 13.07% | -80.82% | -142,141.30% | 88.62% |
| Foreign Exchange rate Adjustments | -96.31% | -110.95% | 57.16% | -54.30% | 1,888.07% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 197.00% | -536.44% | -180.88% | 768.77% | 220.96% |